San Diego, CA — March 10, 2005 — Kalypsys, a privately owned drug discovery company, announced today the appointment of David C. Tiemeier, PhD, as its Chief Commercial Officer. In this role, he will oversee strategic planning, external business development initiatives, and commercialization of the company's pipeline products. Dr. Tiemeier joins Kalypsys at a pivotal point, as the company begins to move candidates into the clinic.
"I have enjoyed working at the interface of science and business, figuring out how to realize the medical benefit of scientific discoveries," commented David C. Tiemeier, PhD. "I'm excited to be joining the Kalypsys team, which includes a number of my former colleagues. The Kalypsys platform has some unique aspects and efficiencies which should favor the delivery of novel therapeutics for the treatment of cardiovascular and metabolic diseases, inflammation and cancer."
Prior to joining Kalypsys, Dr. Tiemeier served as Vice President of Licensing and Development at Immtech International Inc. and Vice President of Business Development at NeoPharm, Inc. Prior to those appointments, he spent 23 years at Pfizer legacy companies Monsanto, Searle and Pharmacia.
While at Monsanto, Dr. Tiemeier spent several years as Senior Fellow and head of Molecular Genetics and Mammalian Biology before transitioning to Searle where he served as Senior Director of Immunoinflammatory and Infectious Diseases and ultimately Vice president of Global Business Development. Dr. Tiemeier also held the position of Vice President of Licensing at Pharmacia.
"We are very pleased that Dr. Tiemeier has accepted the position as Chief Commercial Officer of Kalypsys," commented Kalypsys' President, John McKearn, PhD. "Several members of the management team and Board have had the pleasure of working with Dr. Tiemeier. We are confident that his extensive expertise in inflammatory diseases will add to our success as we prepare to enter the clinic."
Kalypsys is a privately owned San Diego small molecule drug company that uses a suite of validated, ultra-high throughput lead discovery technologies developed initially by the Genomics Institute of the Novartis Research Foundation (GNF). Kalypsys has an integrated drug discovery infrastructure and seasoned team of scientists that are advancing its pipeline into clinical development.
Kalypsys uses its technologies and sizeable drug-like compound collection to improve the drug discovery research process and generate a robust pipeline for itself and its partners. Kalypsys' mission is to build a sustainable drug candidate pipeline from target to proof of efficacy and safety in the clinic with unmatched speed, efficiency, and success rates and currently has a pre-clinical pipeline of small molecule candidates which is advancing rapidly to clinical development. For more information on Kalypsys, please visit www.kalypsys.org.